The presentations will cover a variety of topics, including coronary artery disease, semaglutide, artificial intelligence, TAVR, heart failure, PCI and much more. ACC.25 takes place March 29-31 in Chicago.
Interventional cardiology continues to evolve, driven by rapid advancements in technology. George Dangas, MD, discussed some of the specialty's biggest ongoing trends with Cardiovascular Business.
Researchers have made it a priority to learn as much about the durability of TAVR valves as possible. A new study in JACC: Cardiovascular Interventions used updated VARC-3 definitions to identify signs of hemodynamic valve deterioration in nearly 2,500 patients.
Remote monitoring with the Reveal Linq insertable cardiac monitor can improve outcomes without breaking the bank, according to new data being presented at the International Stroke Conference in Phoenix.
ASNC President Lawrence Phillips, MD, wants to see nuclear cardiologists modernize their labs and embrace new strategies for the evaluation of amyloidosis, sarcoidosis and inflammation.
Back in October, a mobile cardiac imaging provider and its CEO agreed to pay $85 million to settle allegations they had participated in a kickback scheme. This latest DOJ complaint focuses on a former executive not named in that initial settlement.
The American Society of Nuclear Cardiology (ASNC) says positron emission tomography (PET) nuclear imaging has seen wider adoption in the past few years, and many cardiac imaging experts say it could become the workhorse technology for nuclear cardiac assessments over the next decade.
Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
